Advertisement
Advertisement

ABBV

ABBV logo

ABBVIE INC.

201.55
USD
Sponsored
-1.16
-0.57%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

201.25

-0.31
-0.15%

ABBVIE INC. Profile

About

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

Info & Links

CEO

Robert A. Michael

Headquarters

1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064, UNITED STATES

Industry

Large Cap Pharmaceuticals

Sector

Medical

Website

www.abbvie.com

Auditor

Ernst & Young LLP

Share holders

58,040

Employees

57,000

ABBVIE INC. Statistics

Valuation Measures

Market Capitalization2

355.95B

Enterprise Value

418.22B

Enterprise Value/EBITDA(ttm)

17.38

Price to Earnings Ratio(ttm)

21.24

Price to Sales(ttm)

6.14

Price to Book(mrq)

--

Price to Cash(ytd)

14.02

Profitability

Gross Margin(ttm)

70.20%

Operating Margin(ttm)

29.08%

Profit Margin(ttm)

6.90%

Return on Equity(ttm)

-1579.75%

Return on Invested Capital(ttm)

7.02%

Return on Assets(ttm)

13.14%

Income Statement

Revenue(ttm)

61.16B

Revenue Per Share(ttm)

34.59

Gross Profit(ttm)

42.96B

EBITDA(ttm)3

24.06B

Net Income Available to Common(ttm)

4.19B

Diluted EPS(ttm)

2.36

Share Statistics

Beta (5Y Monthly)

0.38

52-Week Change

8.61%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

1.77B

Dividend Yield

3.26%

Float4

1.77B

% Held by Insiders

0.06%

% Held by Institutions

70.23%

Balance Sheet

Total Cash(mrq)

5.26B

Total Cash Per Share(mrq)

2.97

Total Debt(mrq)

67.50B

Total Debt/Equity(mrq)

-2090.95%

Current Ratio(mrq)

0.67%

Quick Ratio(mrq)

0.56%

Book Value Per Share(mrq)

-1.83

Cash Flow

Operating Cash Flow Per Share(ytd)

10.73

Free Cash Flow(ytd)

17.82B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement